Biosergen (BIOSGN) Q3 2025 earnings summary

Executive summary

• Advanced BSG005 development with GMP manufacturing for Cohort 3 and Phase 2, targeting global regulatory standards and commercial readiness in key regions.

• IND submission to the U.S. FDA planned for early next year, supported by positive Phase 1 and proof-of-concept results.

• Mark Beveridge appointed as CFO in July 2025, strengthening the leadership team.

• BSG005 demonstrated strong efficacy and safety in patients with life-threatening, drug-resistant fungal infections, with all treated patients showing recovery or improvement and no severe side effects.

Financial highlights

• Net loss for Q3 2025 was SEK -12.2 million, compared to SEK -4.3 million in Q3 2024, reflecting increased R&D and regulatory preparation.

• Cash and cash equivalents at period end were SEK 22.7 million, up from SEK 10.2 million a year earlier.

• Operating loss for Jan–Sep 2025 was SEK -28.4 million, compared to SEK -16.9 million for the same period in 2024.

• Earnings per share for Jan–Sep 2025 was SEK -0.12, compared to SEK -0.18 for Jan–Sep 2024.

Outlook and guidance

• New GMP batch of BSG005 expected to be released in early 2026, enabling resumption of clinical trials.

• IND submission to the FDA targeted for early 2026, with expanded regulatory engagement in Europe and the U.S.

• Focus remains on advancing BSG005 through clinical development and securing additional funding.